{"gene":"NSD3","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2001,"finding":"NSD3 (WHSC1L1) encodes a SET domain-containing protein with two PWWP domains, five PHD zinc finger motifs, a SAC domain, and a SET domain, and maps to chromosome 8p12; it is amplified in breast cancer cell lines.","method":"Genomic cloning, domain analysis, FISH/chromosomal mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — initial characterization with domain identification and chromosomal mapping across two independent papers (PMID:11374904, PMID:11549311), but no functional reconstitution","pmids":["11374904","11549311"],"is_preprint":false},{"year":2006,"finding":"NSD3/WHISTLE methylates histone H3-K4 and H3-K27 to repress transcription, induces apoptosis via caspase-3 activation dependent on its HMTase activity, and recruits HDAC1 through its N-terminal PWWP region. The SET domain cysteine 297 is critical for HMTase activity, and the PWWP domain is required for HMTase activity by interacting with associating factors.","method":"Deletion mapping, point mutagenesis, in vitro HMTase assay, caspase-3 activation assay, reporter assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis and in vitro activity assays in a single lab with multiple orthogonal methods","pmids":["17239852"],"is_preprint":false},{"year":2010,"finding":"NSD3/WHISTLE interacts with heat shock protein HSP90α and the histone demethylase JMJD1C in a complex (identified by immunoaffinity TAP analysis). WHISTLE is recruited to the p450c17 promoter via SF-1 and represses transcription at prepubertal stages; JMJD1C then replaces WHISTLE to activate target gene expression during mouse testis development.","method":"Immunoaffinity TAP purification, ChIP, reporter assays, RT-PCR","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — TAP purification identifying complex plus ChIP demonstrating chromatin recruitment, single lab","pmids":["20530532"],"is_preprint":false},{"year":2011,"finding":"NSD3 interacts with the extraterminal (ET) domain of BRD4 (and BRD2/BRD3); this interaction is required for pTEFb-independent transcriptional activation. NSD3 is recruited to BRD4 target genes in a BRD4-dependent manner and depletion of BRD4 or NSD3 reduces H3K36 methylation at target genes.","method":"Proteomic pulldown/Co-IP, ChIP, siRNA knockdown, transcriptional reporter assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP for recruitment, functional reporter assay, and histone modification readout in one study; independently corroborated by subsequent structural paper","pmids":["21555454"],"is_preprint":false},{"year":2012,"finding":"The PHD5-C5HCH module of NSD3 forms a novel integrated PHD-PHD-like structural module that binds histone H3 N-terminal peptides, recognizing unmodified H3K4 and trimethylated H3K9 (H3K9me3) via PHD5. This binding specificity differs from NSD1 (which does not bind H3 peptides) and NSD2 (which prefers H3K9me0 over H3K9me3).","method":"Crystal structure determination (apo and H3 peptide-bound states), binding assays (ITC/NMR)","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures in multiple states combined with binding assays in a single rigorous study","pmids":["23269674"],"is_preprint":false},{"year":2012,"finding":"WHSC1L1/NSD3 knockdown causes G2/M cell cycle arrest followed by multinucleation in bladder and lung cancer cell lines, and H3K36 dimethylation (H3K36me2) is reduced; downstream transcriptional targets include CCNG1 and NEK7.","method":"siRNA knockdown, cell cycle analysis (FACS), gene expression profiling (Affymetrix GeneChip)","journal":"Genes, chromosomes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD with defined cellular phenotype and gene expression profiling, single lab","pmids":["23011637"],"is_preprint":false},{"year":2014,"finding":"NSD3 is required for neural crest specification: it is expressed in premigratory and migratory neural crest cells, and is necessary for expression of neural plate border gene Msx1 and neural crest transcription factors Sox10, Snail2, Sox9, and FoxD3. H3K36me2 at the Sox10 locus specifically requires NSD3. A separate, direct requirement for NSD3-related methyltransferase activity exists during neural crest migration (shown by dominant-negative approach restricted to migratory stages).","method":"In situ hybridization, morpholino knockdown, dominant-negative expression (temporal restriction), ChIP for H3K36me2","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined transcriptional phenotypes and H3K36me2 ChIP, single lab","pmids":["25318671"],"is_preprint":false},{"year":2014,"finding":"NSD3-NUT fusion oncoprotein is both necessary and sufficient for blockade of differentiation and maintenance of proliferation in NUT midline carcinoma (NMC) cells. NSD3-NUT binds to BRD4, and BRD4 bromodomain inhibitors reverse its oncogenic effects. NSD3 itself is required for the differentiation block in BRD4-NUT-expressing NMC cells.","method":"Patient-derived cell line establishment, shRNA knockdown, rescue experiments, Co-IP (NSD3-NUT:BRD4 interaction), BET bromodomain inhibitor treatment with differentiation assay","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — necessity and sufficiency experiments, Co-IP, pharmacological validation, replicated across multiple NMC cell lines","pmids":["24875858"],"is_preprint":false},{"year":2015,"finding":"AML maintenance by BRD4 requires its interaction with the short isoform of NSD3 (NSD3-short), which lacks the methyltransferase domain. NSD3-short acts as an adaptor linking BRD4 (via BRD4 ET domain) to the CHD8 chromatin remodeler, using a PWWP chromatin reader module and an acidic transactivation domain. BRD4, NSD3, and CHD8 co-localize at super-enhancers across the AML genome and are co-released upon BET inhibition.","method":"CRISPR/Cas9 and shRNA knockdown (NSD3, CHD8), domain truncation analysis, Co-IP, ChIP-seq (BRD4/NSD3/CHD8 co-localization), RNA-seq, BET inhibitor treatment","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, ChIP-seq, genetic knockouts, transcriptomics), mechanistic isoform dissection, and genome-wide co-localization in single rigorous study","pmids":["26626481"],"is_preprint":false},{"year":2016,"finding":"The ET domain of BRD4 recognizes an amphipathic sequence motif of NSD3 by establishing a two-strand antiparallel β-sheet anchored on a hydrophobic cleft of the ET domain three-helix bundle. This structural mechanism is required for BRD4-NSD3 interaction essential for AML maintenance.","method":"Crystal structure of BRD4 ET domain–NSD3 peptide complex, mutational analysis","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional validation of the interaction mechanism, single lab","pmids":["27291650"],"is_preprint":false},{"year":2016,"finding":"WHSC1L1/NSD3 enrichment and H3K36me2 at gene bodies of CDC6 and CDK2 directly regulates their transcription; WHSC1L1 knockdown causes G0/G1 arrest rescuable by wild-type but not enzyme-inactive WHSC1L1, demonstrating a requirement for catalytic activity in cell cycle progression.","method":"ChIP (WHSC1L1, H3K36me2), siRNA knockdown, rescue with wild-type vs. catalytic mutant, FACS cell cycle analysis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and catalytic mutant rescue, single lab","pmids":["27285764"],"is_preprint":false},{"year":2016,"finding":"WHSC1L1/NSD3 short isoform knockdown dramatically reduces ESR1 mRNA and ERα protein levels in SUM-44 breast cancer cells; loss of WHSC1L1 abrogates estrogen-independent ERα binding to chromatin (assessed by ChIP-Seq), which is restored by estradiol.","method":"siRNA/shRNA knockdown, ChIP-Seq, Western blot, RT-qPCR","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-Seq and genetic knockdown with defined molecular phenotype, single lab","pmids":["27005559"],"is_preprint":false},{"year":2017,"finding":"NSD3/WHSC1L1 directly mono-methylates lysine 721 in the tyrosine kinase domain of EGFR; this methylation enhances ERK cascade activation without EGF and increases nuclear EGFR interaction with PCNA, promoting DNA synthesis and cell cycle progression in head and neck squamous cell carcinoma.","method":"In vitro methylation assay (mass spectrometry identification of K721me1), Co-IP (EGFR-PCNA), siRNA knockdown, cell cycle/DNA synthesis assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro methylation assay with MS validation of site, plus functional cell-based assays, single lab","pmids":["28102297"],"is_preprint":false},{"year":2017,"finding":"NSD3 directly methylates IRF3 at K366 (monomethylation) via its SET domain; NSD3 binds the IRF3 C-terminal region through its PWWP1 domain (identified by mass spectrometry of IRF3-associated proteins). K366 monomethylation enhances IRF3 transcriptional activity by promoting IRF3 dissociation from protein phosphatase PP1cc, thereby maintaining IRF3 phosphorylation and type I interferon production. NSD3 deficiency impairs antiviral innate immune response in vivo.","method":"Mass spectrometry of IRF3-associated proteins, in vitro methylation assay (NSD3 SET domain), domain mapping (PWWP1 binding), Co-IP (NSD3-IRF3, IRF3-PP1cc), site-directed mutagenesis (K366), interferon production assay, in vivo NSD3 knockout","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro methylation assay with site identification by MS, mutagenesis, Co-IP domain mapping, and in vivo KO phenotype in single study","pmids":["29101251"],"is_preprint":false},{"year":2018,"finding":"NSD3-short (NSD3S) interacts with MYC (c-Myc), as detected by cell lysate-based TR-FRET assay, identifying a protein-protein interaction relevant to NSD3S oncogenic activity.","method":"TR-FRET assay (Flag-NSD3, GST-MYC in HEK293T lysates), orthogonal protein-protein interaction assay","journal":"Assay and drug development technologies","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, cell lysate-based indirect detection without reciprocal Co-IP validation","pmids":["29634317"],"is_preprint":false},{"year":2019,"finding":"The PWWP1 domain of NSD3 is required for cancer cell viability; BI-9321, a fragment-based chemical probe, targets the methyl-lysine binding site of NSD3-PWWP1 with sub-micromolar in vitro affinity, engages the target at 1 µM in cells, and downregulates Myc mRNA expression, reducing proliferation in MOLM-13 AML cells.","method":"Fragment-based drug discovery (NMR, X-ray crystallography of probe-PWWP1 complex), cellular target engagement assay, qRT-PCR (Myc expression), cell proliferation assay","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structural characterization of PWWP1-ligand complex combined with cellular target engagement and functional readout in a single rigorous study","pmids":["31285596"],"is_preprint":false},{"year":2019,"finding":"NSD3 overexpression activates ERK1/2 signaling and enhances CAPG expression in colorectal cancer cells, promoting proliferation and migration; these effects are partially reversed by ERK1/2 inhibitor (PD98059) or CAPG siRNA.","method":"siRNA knockdown, overexpression, Western blot (ERK1/2 phosphorylation), cell proliferation and migration assays, pharmacological inhibition","journal":"OncoTargets and therapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, indirect pathway measurement without direct biochemical demonstration of ERK activation mechanism","pmids":["31190890"],"is_preprint":false},{"year":2020,"finding":"NSD3 long isoform (full-length, with catalytic domain), but not the short isoform lacking the catalytic domain, cooperates with EZH2 and RNA polymerase II to drive H3K36me2/3-dependent transactivation of genes associated with NOTCH receptor cleavage, leading to nuclear accumulation of NICD and NICD-mediated transcriptional repression of E-cadherin. This promotes breast cancer cell stemness, EMT, and metastasis.","method":"Isoform-specific knockdown/overexpression, ChIP (H3K36me2/3, RNA Pol II), Co-IP (NSD3-EZH2), NOTCH pathway reporter, NICD nuclear localization assay, E-cadherin promoter ChIP, in vivo mouse tumor model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (ChIP, Co-IP, isoform dissection, in vivo), single lab","pmids":["32967925"],"is_preprint":false},{"year":2021,"finding":"NSD3 is a catalytically active H3K36me2 methyltransferase and a key driver of lung squamous cell carcinoma (LUSC). An LUSC-associated variant NSD3(T1232A) shows increased catalytic activity for H3K36me2 in vitro and in vivo due to structural changes that relieve auto-inhibition. Expression of NSD3(T1232A) accelerates tumorigenesis in mouse models of LUSC. NSD3-dependent oncogenic activity requires its catalytic activity and promotes oncogenic gene expression via chromatin landscape reprogramming. NSD3-amplified/mutant LUSCs are hypersensitive to bromodomain inhibition.","method":"In vitro methylation assays, structural dynamic analysis (MD simulations), mouse LUSC models (KO and knock-in), patient-derived xenograft, CRISPR/Cas9, ChIP (H3K36me2), gene expression profiling, BET inhibitor treatment","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation reconstitution, structural analysis, multiple in vivo mouse models, and patient-derived xenograft, multiple orthogonal methods","pmids":["33536620"],"is_preprint":false},{"year":2021,"finding":"NSD3 PROTAC degrader MS9715 (linking BI-9321/PWWP1 antagonist to VHL E3 ligase ligand) achieves selective NSD3 degradation and suppresses both NSD3 and cMyc oncogenic transcriptional programs in hematological cancer cells, with superior efficacy over PWWP1 blockade alone.","method":"PROTAC degradation assay, Western blot, transcriptomic profiling (RNA-seq), CRISPR-Cas9 NSD3 KO comparison, cell growth assay","journal":"Cell chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological degradation with genetic KO comparison and transcriptomic profiling, single lab","pmids":["34469831"],"is_preprint":false},{"year":2023,"finding":"NSD3 is essential for mitotic sister chromatid cohesion: the long isoform interacts with the cohesin loader complex kollerin (NIPBL-MAU2) and promotes chromatin recruitment of MAU2 and cohesin at mitotic exit. NSD3 associates with chromatin in early anaphase prior to MAU2 and RAD21 recruitment, and its methyltransferase activity is required for efficient sister chromatid cohesion.","method":"Co-IP (NSD3-NIPBL/MAU2), ChIP (NSD3, MAU2, RAD21), siRNA knockdown with cohesion assay (sister chromatid separation), isoform-specific rescue, methyltransferase-dead mutant rescue","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP, functional cohesion assay, and methyltransferase-dead mutant in single study, single lab","pmids":["37288770"],"is_preprint":false},{"year":2024,"finding":"NSD3 deposits H3K36me2 specifically at active promoters and enhancers (in contrast to NSD1/NSD2 which deposit H3K36me2 at broad intergenic regions). In the hierarchy of H3K36me1/2 deposition, NSD1 > NSD2 > NSD3 > ASH1L.","method":"Systematic genetic perturbations (single and combinatorial KO) in mouse mesenchymal stem cells, ChIP-seq (H3K36me1/2/3), comparative genomic analysis","journal":"Genome biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic multi-KO approach with genome-wide ChIP-seq across five methyltransferases, published in peer-reviewed journal","pmids":["39390582"],"is_preprint":false},{"year":2024,"finding":"NSD3 forms a trimer with PPP1CB and p-STAT3 at the protein level (Co-IP), facilitating PPP1CB-mediated dephosphorylation of STAT3, which suppresses HK2 transcription and glycolysis in lung adenocarcinoma cells. This is a non-epigenetic function of NSD3.","method":"Co-IP (NSD3-PPP1CB-p-STAT3 trimer), Western blot (p-STAT3 levels), ChIP (HK2 promoter), glycolysis assay (glucose uptake, lactate production), siRNA knockdown","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifying trimer, functional phosphatase assay readout, and glycolysis measurements; single lab","pmids":["39119928"],"is_preprint":false},{"year":2024,"finding":"EHMT2 interacts with and methylates NSD3 at lysine 477, stabilizing NSD3 protein levels in variant human embryonic stem cells; NSD3 protein levels are regulated by protein degradation in normal hESCs, and methylation-mediated stabilization drives oncogenic transformation.","method":"Co-IP (EHMT2-NSD3), mass spectrometry identification of K477 methylation, NSD3 knockdown rescue experiments, protein stability assay (cycloheximide chase), cell transformation assays","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with MS identification of methylation site plus functional protein stability assays; single lab","pmids":["39741006"],"is_preprint":false},{"year":2025,"finding":"The short isoform of NSD3 (NSD3S, lacking methyltransferase domain) is upregulated by impaired CUL3-ZBTB2 E3 ubiquitin ligase-mediated degradation; ATR kinase drives localization of NSD3S to stalled replication forks where it antagonizes PTIP-dependent MRE11 nuclease recruitment, protecting nascent DNA from degradation and stabilizing stalled forks, thereby conferring PARP inhibitor resistance in prostate cancer.","method":"Co-IP (NSD3S-PTIP, NSD3S-MRE11), proximity ligation assay (NSD3S at replication forks), iPOND (isolation of proteins on nascent DNA), siRNA/shRNA knockdown, PROTAC degradation, cell-line and PDX xenograft models, PARP inhibitor sensitivity assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, iPOND/fork protection assay, PROTAC degradation), in vivo PDX validation, and mechanistic isoform dissection in a single rigorous study","pmids":["40578344"],"is_preprint":false},{"year":2025,"finding":"NSD3 long isoform (NSD3L) localizes to the nucleolus, binds nucleolar proteins, and triggers ribosomal DNA (rDNA) transcription by promoting Polymerase I and UBTF binding to the rDNA locus, while displacing the transcriptional repressor FOSL2 from the rDNA upstream region. NSD3L also prevents deposition of repressive H4K20me3 by competing with SUV4-20H.","method":"Unbiased mass spectrometry (nucleolar protein binding), ChIP (Pol I, UBTF, FOSL2, H4K20me3 on rDNA), NSD3L knockout/ablation, nucleolar localization by imaging, rRNA expression assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS identification of nucleolar partners, ChIP on rDNA locus for multiple factors, functional rRNA output assay; single lab","pmids":["42082455"],"is_preprint":false},{"year":2026,"finding":"NSD3 (via its long isoform) mediates chromosome folding in NUT carcinoma cells: it stabilizes the BRD4-NUT fusion oncoprotein on chromatin, promotes H3K36me2, and supports BRD4-NUT nuclear condensates; NSD3 loss attenuates distant chromatin interactions between BRD4-NUT megadomains. In fusion-negative cells, NSD3-short (catalytically inactive) promotes long-range chromatin contacts (>megabases) in a PWWP domain-dependent manner.","method":"Hi-C/chromatin conformation capture, ChIP-seq (H3K36me2, BRD4-NUT), CRISPR NSD3 knockout, domain-mutant NSD3 (PWWP mutant), live-cell imaging of condensates, fractionation","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Hi-C and ChIP-seq with genetic KO and domain mutant, but preprint only","pmids":["41727024"],"is_preprint":true}],"current_model":"NSD3 is a histone H3K36 mono/dimethyltransferase that deposits H3K36me2 preferentially at active promoters and enhancers; it exists in a catalytically active long isoform and a short isoform (NSD3S) lacking the SET domain that functions as a chromatin adaptor linking BRD4 (via its ET domain, through a defined amphipathic motif interaction) to the CHD8 remodeler; it also directly methylates non-histone substrates including IRF3 (K366) to promote interferon production and EGFR (K721) to enhance oncogenic signaling, is itself stabilized by EHMT2-mediated K477 methylation, promotes cohesin loading at mitotic exit through interaction with the kollerin complex (NIPBL-MAU2), drives rDNA transcription by displacing FOSL2 and competing with SUV4-20H at rDNA, and in its short isoform localizes to stalled replication forks (ATR-dependent) to protect nascent DNA by antagonizing MRE11 recruitment, thereby conferring PARP inhibitor resistance."},"narrative":{"mechanistic_narrative":"NSD3 (WHSC1L1) is a multidomain SET-domain histone methyltransferase that deposits H3K36 mono/dimethylation specifically at active promoters and enhancers, distinguishing it from the broad intergenic H3K36me2 patterns laid down by NSD1 and NSD2 [PMID:11374904, PMID:11549311, PMID:39390582]. Its catalytic activity drives transcription of cell-cycle genes such as CDC6 and CDK2, and enzyme-dead mutants fail to rescue the proliferation defects of NSD3-depleted cells, establishing a direct catalytic requirement for cell-cycle progression [PMID:23011637, PMID:27285764]. NSD3 also acts as a developmental regulator, supplying H3K36me2 required for neural crest specification gene expression [PMID:25318671]. Histone-tail engagement is structurally encoded: an integrated PHD5-C5HCH module reads unmodified H3K4 and H3K9me3, while a PWWP1 methyl-lysine reader module is essential for cancer-cell viability and serves as a druggable pocket targeted by the BI-9321 chemical probe and the MS9715 PROTAC degrader, both of which suppress NSD3- and cMyc-driven transcriptional programs [PMID:23269674, PMID:31285596, PMID:34469831]. NSD3 is expressed as a catalytically active long isoform and a short isoform (NSD3S) lacking the SET domain that functions as a chromatin adaptor: NSD3S bridges BRD4 — through a defined amphipathic motif that forms an antiparallel β-sheet on the BRD4 ET-domain three-helix bundle — to the CHD8 remodeler, and this adaptor function sustains acute myeloid leukemia and the differentiation block of NUT midline carcinoma [PMID:21555454, PMID:26626481, PMID:27291650, PMID:24875858]. Beyond chromatin, NSD3 methylates non-histone substrates, monomethylating EGFR at K721 to potentiate oncogenic ERK signaling and IRF3 at K366 to enhance type I interferon production by displacing PP1cc and maintaining IRF3 phosphorylation [PMID:28102297, PMID:29101251]. The long isoform additionally promotes mitotic sister-chromatid cohesion by recruiting the kollerin (NIPBL-MAU2) cohesin loader at mitotic exit, while NSD3S protects stalled replication forks in an ATR-dependent manner by antagonizing MRE11 recruitment, conferring PARP-inhibitor resistance [PMID:37288770, PMID:40578344]. NSD3 is recurrently amplified and mutated in epithelial cancers, and a catalytically hyperactive variant (T1232A) accelerates lung squamous cell carcinoma, defining NSD3 as an oncogenic methyltransferase whose tumors are hypersensitive to bromodomain inhibition [PMID:11374904, PMID:11549311, PMID:33536620].","teleology":[{"year":2001,"claim":"Establishing the domain architecture and genomic location framed NSD3 as a candidate chromatin-modifying enzyme amplified in cancer.","evidence":"Genomic cloning, domain analysis, and FISH mapping to 8p12 in breast cancer cell lines","pmids":["11374904","11549311"],"confidence":"Medium","gaps":["No catalytic activity reconstituted","Substrate specificity unknown at this stage"]},{"year":2006,"claim":"First functional dissection assigned methyltransferase activity to the SET domain and a regulatory role to the PWWP region, though the histone substrate assignment differs from later consensus.","evidence":"Deletion mapping, point mutagenesis (C297), in vitro HMTase and caspase-3 assays","pmids":["17239852"],"confidence":"Medium","gaps":["Reported H3K4/H3K27 substrate not concordant with later H3K36 consensus","Single-lab in vitro context"]},{"year":2011,"claim":"Identifying the BRD4 ET-domain interaction explained how NSD3 is targeted to active genes and coupled to pTEFb-independent transcription.","evidence":"Co-IP, ChIP recruitment, siRNA knockdown, reporter assay, H3K36 methylation readout","pmids":["21555454"],"confidence":"High","gaps":["Did not resolve which isoform mediates the interaction","Structural basis not yet defined"]},{"year":2012,"claim":"Crystallography of the PHD5-C5HCH module and cell-cycle knockdown studies defined how NSD3 reads histone tails and linked its loss to mitotic defects.","evidence":"Crystal structures with H3 peptides plus ITC/NMR binding; siRNA with FACS cell-cycle analysis and expression profiling","pmids":["23269674","23011637"],"confidence":"High","gaps":["Functional consequence of H3K9me3 recognition in vivo unresolved","Connection between reader binding and catalysis not established"]},{"year":2014,"claim":"Loss-of-function in neural crest and the discovery of the NSD3-NUT fusion oncoprotein established NSD3 in both normal development and oncogenic gene-regulatory programs through BRD4.","evidence":"Morpholino/dominant-negative with H3K36me2 ChIP in embryo; patient cell lines, shRNA, rescue, Co-IP, BET inhibitor in NUT carcinoma","pmids":["25318671","24875858"],"confidence":"Medium","gaps":["Direct catalytic versus scaffold contribution to NUT carcinoma not separated at this point","In vivo developmental substrate scope incomplete"]},{"year":2015,"claim":"Isoform dissection revealed that the catalytically inactive short isoform, not the methyltransferase, is the adaptor coupling BRD4 to CHD8 at super-enhancers, redefining NSD3's role in AML.","evidence":"CRISPR/shRNA, domain truncation, Co-IP, BRD4/NSD3/CHD8 ChIP-seq co-localization, RNA-seq, BET inhibition","pmids":["26626481"],"confidence":"High","gaps":["Mechanism of CHD8 engagement structurally undefined here","Whether catalytic isoform contributes independently unresolved"]},{"year":2016,"claim":"Structural and functional work converged to define the BRD4-ET–NSD3 amphipathic interface and to nail down a strict catalytic requirement for cell-cycle gene transcription and ERα chromatin binding.","evidence":"Crystal structure of ET–NSD3 peptide complex; catalytic-mutant rescue ChIP at CDC6/CDK2; ChIP-seq of ERα in breast cancer","pmids":["27291650","27285764","27005559"],"confidence":"High","gaps":["How catalytic and scaffold functions are partitioned between isoforms in the same cell remains unclear","ERα regulatory mechanism downstream of NSD3 undefined"]},{"year":2017,"claim":"Identification of EGFR-K721 and IRF3-K366 as direct substrates extended NSD3 beyond histones into oncogenic signaling and antiviral immunity.","evidence":"In vitro methylation with MS site mapping, domain mapping, Co-IP, mutagenesis, interferon assays, in vivo NSD3 knockout","pmids":["28102297","29101251"],"confidence":"High","gaps":["Full non-histone substrate repertoire unknown","In vivo stoichiometry and dynamics of these methylations not quantified"]},{"year":2018,"claim":"An NSD3S–MYC interaction was reported, hinting at a direct link to the Myc oncogenic program.","evidence":"Cell lysate TR-FRET assay between Flag-NSD3 and GST-MYC","pmids":["29634317"],"confidence":"Low","gaps":["Indirect lysate-based detection without reciprocal Co-IP validation","No structural or cellular confirmation of the interaction"]},{"year":2019,"claim":"Chemical-probe and PROTAC development validated the PWWP1 methyl-lysine pocket as a tractable target whose engagement downregulates Myc and impairs leukemia growth.","evidence":"Fragment-based discovery with NMR/X-ray of probe-PWWP1 complex, cellular target engagement, qRT-PCR, proliferation; colorectal overexpression studies","pmids":["31285596","31190890"],"confidence":"High","gaps":["Mechanistic link between PWWP1 occupancy and Myc transcription incompletely defined","Colorectal ERK/CAPG axis (Low confidence) lacks direct biochemical demonstration"]},{"year":2020,"claim":"Isoform-specific work showed the long catalytic isoform cooperates with EZH2 and Pol II to drive NOTCH-dependent EMT and metastasis, distinguishing catalytic from adaptor functions.","evidence":"Isoform knockdown/overexpression, H3K36me2/3 and Pol II ChIP, NSD3-EZH2 Co-IP, NOTCH reporter, in vivo tumor model","pmids":["32967925"],"confidence":"Medium","gaps":["Direct NSD3-EZH2 structural interface not defined","Single-lab context"]},{"year":2021,"claim":"Comprehensive in vivo and structural work established NSD3 as a bona fide H3K36me2 oncogenic driver in LUSC and showed a hyperactive variant relieves auto-inhibition to accelerate tumorigenesis.","evidence":"In vitro methylation, MD simulations, mouse KO/knock-in LUSC models, PDX, CRISPR, ChIP, BET inhibition; PROTAC MS9715 degradation with KO comparison","pmids":["33536620","34469831"],"confidence":"High","gaps":["Endogenous regulators of the auto-inhibitory conformation in normal cells unknown","Relationship between catalytic LUSC driving and BET-inhibitor sensitivity mechanistically incomplete"]},{"year":2023,"claim":"NSD3 was assigned a mitotic role, with the long isoform recruiting the kollerin cohesin loader and requiring catalytic activity for sister-chromatid cohesion.","evidence":"Co-IP with NIPBL/MAU2, ChIP of NSD3/MAU2/RAD21, cohesion assays, isoform- and methyltransferase-dead rescue","pmids":["37288770"],"confidence":"Medium","gaps":["Methyl substrate underlying cohesion promotion not identified","Single-lab finding awaiting independent confirmation"]},{"year":2024,"claim":"Multiple studies refined NSD3's genomic targeting specificity, identified additional non-epigenetic and regulatory functions, and defined how NSD3 itself is post-translationally stabilized.","evidence":"Systematic multi-KO ChIP-seq in mesenchymal stem cells; NSD3-PPP1CB-pSTAT3 trimer Co-IP and glycolysis assays; EHMT2-NSD3 Co-IP with K477 methylation MS and stability assays","pmids":["39390582","39119928","39741006"],"confidence":"High","gaps":["Mechanism directing NSD3 specifically to active promoters/enhancers undefined","Generality of the STAT3 trimer function beyond lung adenocarcinoma unknown"]},{"year":2025,"claim":"New work defined isoform-segregated functions in genome stability and rDNA transcription, with NSD3S protecting stalled forks (PARPi resistance) and NSD3L driving Pol I transcription in the nucleolus.","evidence":"Co-IP, PLA, iPOND fork protection, PROTAC, PDX and PARPi assays; nucleolar MS, rDNA ChIP of Pol I/UBTF/FOSL2/H4K20me3, NSD3L ablation","pmids":["40578344","42082455"],"confidence":"High","gaps":["Whether fork protection requires catalytic activity unresolved","Direct methyl substrate at the rDNA locus not identified"]},{"year":2026,"claim":"Chromosome-folding analyses linked NSD3 isoforms to 3D genome organization, stabilizing BRD4-NUT condensates and mediating long-range chromatin contacts.","evidence":"Hi-C, ChIP-seq, CRISPR KO, PWWP domain mutants, condensate imaging (preprint)","pmids":["41727024"],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed","Mechanism by which catalytically inactive NSD3S drives megabase-scale contacts undefined"]},{"year":null,"claim":"How NSD3 isoform choice, catalytic versus scaffold activities, genomic targeting, and its expanding non-histone substrate set are integrated into a single regulatory logic across normal and malignant cells remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking targeting specificity to substrate selection","Endogenous control of long-versus-short isoform ratio incompletely defined","Complete non-histone methylome unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[12,13]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[5,10,18,21]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[4]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[8,9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,8,20]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[8,21,24]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[25]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[8,21]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,10,17]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[5,10,20]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13]}],"complexes":["kollerin (NIPBL-MAU2)"],"partners":["BRD4","CHD8","EZH2","NIPBL","MAU2","EHMT2","PPP1CB","PTIP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BZ95","full_name":"Histone-lysine N-methyltransferase NSD3","aliases":["Nuclear SET domain-containing protein 3","Protein whistle","WHSC1-like 1 isoform 9 with methyltransferase activity to lysine","Wolf-Hirschhorn syndrome candidate 1-like protein 1","WHSC1-like protein 1"],"length_aa":1437,"mass_kda":161.6,"function":"Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K4me2 and H3K27me2. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation, while 'Lys-27' is a mark for transcriptional repression","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/Q9BZ95/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NSD3","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CBX1","stoichiometry":0.2},{"gene":"DHX9","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"LAMTOR2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/NSD3","total_profiled":1310},"omim":[{"mim_id":"607083","title":"NUCLEAR RECEPTOR-BINDING SET DOMAIN PROTEIN 3; NSD3","url":"https://www.omim.org/entry/607083"},{"mim_id":"603395","title":"SPERM-ASSOCIATED ANTIGEN 1; SPAG1","url":"https://www.omim.org/entry/603395"},{"mim_id":"601021","title":"NUCLEOPORIN, 98-KD; NUP98","url":"https://www.omim.org/entry/601021"},{"mim_id":"117550","title":"SOTOS SYNDROME; SOTOS","url":"https://www.omim.org/entry/117550"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NSD3"},"hgnc":{"alias_symbol":["FLJ20353","WHISTLE","KMT3F"],"prev_symbol":["WHSC1L1"]},"alphafold":{"accession":"Q9BZ95","domains":[{"cath_id":"2.30.30.140","chopping":"273-351_364-396","consensus_level":"high","plddt":86.3593,"start":273,"end":396},{"cath_id":"3.30.40","chopping":"705-750","consensus_level":"medium","plddt":82.1078,"start":705,"end":750},{"cath_id":"3.30.40.10","chopping":"855-870_920-956","consensus_level":"medium","plddt":72.0947,"start":855,"end":956},{"cath_id":"2.30.30.140","chopping":"958-1023_1036-1067","consensus_level":"medium","plddt":83.8032,"start":958,"end":1067},{"cath_id":"2.170.270.10","chopping":"1077-1289","consensus_level":"high","plddt":90.3759,"start":1077,"end":1289},{"cath_id":"3.30.40.10","chopping":"1334-1422","consensus_level":"medium","plddt":84.9344,"start":1334,"end":1422}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZ95","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZ95-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZ95-F1-predicted_aligned_error_v6.png","plddt_mean":61.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NSD3","jax_strain_url":"https://www.jax.org/strain/search?query=NSD3"},"sequence":{"accession":"Q9BZ95","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BZ95.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BZ95/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZ95"}},"corpus_meta":[{"pmid":"21555454","id":"PMC_21555454","title":"The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/21555454","citation_count":442,"is_preprint":false},{"pmid":"24875858","id":"PMC_24875858","title":"NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.","date":"2014","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/24875858","citation_count":211,"is_preprint":false},{"pmid":"30993345","id":"PMC_30993345","title":"WHISTLE: a high-accuracy map of the human N6-methyladenosine (m6A) epitranscriptome predicted using a machine learning approach.","date":"2019","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/30993345","citation_count":178,"is_preprint":false},{"pmid":"11986249","id":"PMC_11986249","title":"NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15).","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11986249","citation_count":153,"is_preprint":false},{"pmid":"11374904","id":"PMC_11374904","title":"NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11374904","citation_count":139,"is_preprint":false},{"pmid":"26626481","id":"PMC_26626481","title":"NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26626481","citation_count":133,"is_preprint":false},{"pmid":"33536620","id":"PMC_33536620","title":"Elevated NSD3 histone methylation activity drives squamous cell lung cancer.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33536620","citation_count":128,"is_preprint":false},{"pmid":"31285596","id":"PMC_31285596","title":"Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3.","date":"2019","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/31285596","citation_count":76,"is_preprint":false},{"pmid":"20530532","id":"PMC_20530532","title":"Regulation of mouse steroidogenesis by WHISTLE and JMJD1C through histone methylation balance.","date":"2010","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/20530532","citation_count":67,"is_preprint":false},{"pmid":"17705804","id":"PMC_17705804","title":"Testicular cancer trends as 'whistle blowers' of testicular developmental problems in populations.","date":"2007","source":"International journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/17705804","citation_count":66,"is_preprint":false},{"pmid":"32967925","id":"PMC_32967925","title":"NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32967925","citation_count":65,"is_preprint":false},{"pmid":"27291650","id":"PMC_27291650","title":"Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4.","date":"2016","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/27291650","citation_count":64,"is_preprint":false},{"pmid":"23011637","id":"PMC_23011637","title":"The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.","date":"2012","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23011637","citation_count":60,"is_preprint":false},{"pmid":"23269674","id":"PMC_23269674","title":"The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23269674","citation_count":53,"is_preprint":false},{"pmid":"29101251","id":"PMC_29101251","title":"The methyltransferase NSD3 promotes antiviral innate immunity via direct lysine methylation of IRF3.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29101251","citation_count":51,"is_preprint":false},{"pmid":"22389394","id":"PMC_22389394","title":"No one can whistle a symphony alone - how different ubiquitin linkages cooperate to orchestrate NF-κB activity.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22389394","citation_count":51,"is_preprint":false},{"pmid":"11549311","id":"PMC_11549311","title":"WHSC1L1, on human chromosome 8p11.2, closely resembles WHSC1 and maps to a duplicated region shared with 4p16.3.","date":"2001","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/11549311","citation_count":50,"is_preprint":false},{"pmid":"34469831","id":"PMC_34469831","title":"A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells.","date":"2021","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/34469831","citation_count":47,"is_preprint":false},{"pmid":"35532818","id":"PMC_35532818","title":"The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35532818","citation_count":45,"is_preprint":false},{"pmid":"19380029","id":"PMC_19380029","title":"NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes.","date":"2009","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19380029","citation_count":45,"is_preprint":false},{"pmid":"28102297","id":"PMC_28102297","title":"WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28102297","citation_count":43,"is_preprint":false},{"pmid":"25466466","id":"PMC_25466466","title":"NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue.","date":"2014","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/25466466","citation_count":39,"is_preprint":false},{"pmid":"27285764","id":"PMC_27285764","title":"WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27285764","citation_count":38,"is_preprint":false},{"pmid":"27005559","id":"PMC_27005559","title":"Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer.","date":"2016","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27005559","citation_count":38,"is_preprint":false},{"pmid":"24051013","id":"PMC_24051013","title":"PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24051013","citation_count":34,"is_preprint":false},{"pmid":"15483650","id":"PMC_15483650","title":"Evaluation of NSD2 and NSD3 in overgrowth syndromes.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15483650","citation_count":33,"is_preprint":false},{"pmid":"25685583","id":"PMC_25685583","title":"Cytological Features of a Variant NUT Midline Carcinoma of the Lung Harboring the NSD3-NUT Fusion Gene: A Case Report and Literature Review.","date":"2015","source":"Case reports in pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25685583","citation_count":32,"is_preprint":false},{"pmid":"35717870","id":"PMC_35717870","title":"Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.","date":"2022","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35717870","citation_count":31,"is_preprint":false},{"pmid":"34997561","id":"PMC_34997561","title":"Thyroid Carcinoma with NSD3::NUTM1 Fusion: a Case with Thyrocyte Differentiation and Colloid Production.","date":"2022","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34997561","citation_count":28,"is_preprint":false},{"pmid":"30013365","id":"PMC_30013365","title":"The role of histone lysine methyltransferase NSD3 in cancer.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30013365","citation_count":25,"is_preprint":false},{"pmid":"28781807","id":"PMC_28781807","title":"Amplification of the NSD3-BRD4-CHD8 pathway in pelvic high-grade serous carcinomas of tubo-ovarian and endometrial origin.","date":"2017","source":"Molecular and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28781807","citation_count":25,"is_preprint":false},{"pmid":"36040068","id":"PMC_36040068","title":"NUTM1 -rearranged Carcinoma of the Thyroid : A Distinct Subset of NUT Carcinoma Characterized by Frequent NSD3 - NUTM1 Fusions.","date":"2022","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36040068","citation_count":25,"is_preprint":false},{"pmid":"28901481","id":"PMC_28901481","title":"Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28901481","citation_count":24,"is_preprint":false},{"pmid":"25318671","id":"PMC_25318671","title":"Neural crest specification and migration independently require NSD3-related lysine methyltransferase activity.","date":"2014","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/25318671","citation_count":22,"is_preprint":false},{"pmid":"31190890","id":"PMC_31190890","title":"Downregulation of NSD3 (WHSC1L1) inhibits cell proliferation and migration via ERK1/2 deactivation and decreasing CAPG expression in colorectal cancer cells.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31190890","citation_count":19,"is_preprint":false},{"pmid":"28484924","id":"PMC_28484924","title":"Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3.","date":"2017","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/28484924","citation_count":18,"is_preprint":false},{"pmid":"29634317","id":"PMC_29634317","title":"Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction.","date":"2018","source":"Assay and drug development technologies","url":"https://pubmed.ncbi.nlm.nih.gov/29634317","citation_count":16,"is_preprint":false},{"pmid":"39390582","id":"PMC_39390582","title":"Systematic perturbations of SETD2, NSD1, NSD2, NSD3, and ASH1L reveal their distinct contributions to H3K36 methylation.","date":"2024","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/39390582","citation_count":15,"is_preprint":false},{"pmid":"33891143","id":"PMC_33891143","title":"NSD3-NUTM1-rearranged carcinoma of the median neck/thyroid bed developing after recent thyroidectomy for sclerosing mucoepidermoid carcinoma with eosinophilia: report of an extraordinary case.","date":"2021","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33891143","citation_count":14,"is_preprint":false},{"pmid":"39119928","id":"PMC_39119928","title":"Histones Methyltransferase NSD3 Inhibits Lung Adenocarcinoma Glycolysis Through Interacting with PPP1CB to Decrease STAT3 Signaling Pathway.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39119928","citation_count":13,"is_preprint":false},{"pmid":"37182335","id":"PMC_37182335","title":"NSD3: Advances in cancer therapeutic potential and inhibitors research.","date":"2023","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37182335","citation_count":13,"is_preprint":false},{"pmid":"34440470","id":"PMC_34440470","title":"Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34440470","citation_count":13,"is_preprint":false},{"pmid":"17239852","id":"PMC_17239852","title":"The histone methyltransferase activity of WHISTLE is important for the induction of apoptosis and HDAC1-mediated transcriptional repression.","date":"2006","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/17239852","citation_count":13,"is_preprint":false},{"pmid":"36291782","id":"PMC_36291782","title":"Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36291782","citation_count":12,"is_preprint":false},{"pmid":"28903324","id":"PMC_28903324","title":"The PWWP domain of the human oncogene WHSC1L1/NSD3 induces a metabolic shift toward fermentation.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28903324","citation_count":11,"is_preprint":false},{"pmid":"34245870","id":"PMC_34245870","title":"WHISTLE server: A high-accuracy genomic coordinate-based machine learning platform for RNA modification prediction.","date":"2021","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/34245870","citation_count":11,"is_preprint":false},{"pmid":"33835461","id":"PMC_33835461","title":"WHISTLE: A Functionally Annotated High-Accuracy Map of Human m6A Epitranscriptome.","date":"2021","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/33835461","citation_count":9,"is_preprint":false},{"pmid":"31254363","id":"PMC_31254363","title":"Protective effect of histone methyltransferase NSD3 on ISO-induced cardiac hypertrophy.","date":"2019","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/31254363","citation_count":8,"is_preprint":false},{"pmid":"37072259","id":"PMC_37072259","title":"Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain.","date":"2023","source":"Chemical biology & drug design","url":"https://pubmed.ncbi.nlm.nih.gov/37072259","citation_count":8,"is_preprint":false},{"pmid":"34357103","id":"PMC_34357103","title":"High WHSC1L1 Expression Reduces Survival Rates in Operated Breast Cancer Patients with Decreased CD8+ T Cells: Machine Learning Approach.","date":"2021","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34357103","citation_count":8,"is_preprint":false},{"pmid":"38256018","id":"PMC_38256018","title":"NSD3 in Cancer: Unraveling Methyltransferase-Dependent and Isoform-Specific Functions.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38256018","citation_count":6,"is_preprint":false},{"pmid":"22131849","id":"PMC_22131849","title":"A case of autologous microfat grafting in lip reconstruction of a whistle deformity following cancer treatment.","date":"2010","source":"The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique","url":"https://pubmed.ncbi.nlm.nih.gov/22131849","citation_count":6,"is_preprint":false},{"pmid":"37400043","id":"PMC_37400043","title":"Prospect of targeting lysine methyltransferase NSD3 for tumor therapy.","date":"2023","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/37400043","citation_count":5,"is_preprint":false},{"pmid":"35502835","id":"PMC_35502835","title":"Rhabdomyosarcoma With Epithelioid Features And NSD3::FOXO1 Fusion: Evidence For Reconsideration Of Previously Reported FOXO1::FGFR1 Fusion.","date":"2022","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35502835","citation_count":5,"is_preprint":false},{"pmid":"35880417","id":"PMC_35880417","title":"Possible Primary Thyroid Nuclear Protein in Testis Carcinomas with NSD3::NUTM1 Translocation Revealed by RNA Sequencing: A Report of Two Cases.","date":"2022","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/35880417","citation_count":5,"is_preprint":false},{"pmid":"37748280","id":"PMC_37748280","title":"WHSC1L1-mediated epigenetic downregulation of VMP1 participates in herpes simplex virus 1 infection-induced mitophagy impairment and neuroinflammation.","date":"2023","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37748280","citation_count":4,"is_preprint":false},{"pmid":"39628352","id":"PMC_39628352","title":"Targeted RNA sequencing in diagnostically challenging head and neck carcinomas identifies novel MON2::STAT6, NFATC2::NUTM2B, POC5::RAF1, and NSD3::NCOA2 gene fusions.","date":"2024","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/39628352","citation_count":4,"is_preprint":false},{"pmid":"37288770","id":"PMC_37288770","title":"The histone methyltransferase NSD3 contributes to sister chromatid cohesion and to cohesin loading at mitotic exit.","date":"2023","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/37288770","citation_count":4,"is_preprint":false},{"pmid":"40578344","id":"PMC_40578344","title":"Isoform-specific function of NSD3 in DNA replication stress confers resistance to PARP inhibitors in prostate cancer.","date":"2025","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/40578344","citation_count":3,"is_preprint":false},{"pmid":"37905045","id":"PMC_37905045","title":"Systematic perturbations of SETD2, NSD1, NSD2, NSD3 and ASH1L reveals their distinct contributions to H3K36 methylation.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/37905045","citation_count":3,"is_preprint":false},{"pmid":"31563542","id":"PMC_31563542","title":"High yield recombinant expression and purification of oncogenic NSD1, NSD2, and NSD3 with human influenza hemagglutinin tag.","date":"2019","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/31563542","citation_count":3,"is_preprint":false},{"pmid":"39200173","id":"PMC_39200173","title":"NSD3::NUTM1 Fusion Sarcoma Mimicking Malignant Peripheral Nerve Sheath Tumor with Prolonged Survival.","date":"2024","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/39200173","citation_count":3,"is_preprint":false},{"pmid":"35303440","id":"PMC_35303440","title":"Degradation of NSD3: What to Myc of it all?","date":"2022","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35303440","citation_count":2,"is_preprint":false},{"pmid":"40036479","id":"PMC_40036479","title":"NSD3::FGFR1 : A Novel Gene Fusion First to Be Described in Merkel Cell Carcinoma.","date":"2025","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/40036479","citation_count":2,"is_preprint":false},{"pmid":"40792216","id":"PMC_40792216","title":"Acquisition of FGFR1 and NSD3 Amplifications During the Transformation of EGFR-Mutated Lung Adenocarcinoma into Squamous Cell Carcinoma: A Case Report.","date":"2025","source":"JTO clinical and research reports","url":"https://pubmed.ncbi.nlm.nih.gov/40792216","citation_count":2,"is_preprint":false},{"pmid":"38516186","id":"PMC_38516186","title":"Structural insights into the C-terminus of the histone-lysine N-methyltransferase NSD3 by small-angle X-ray scattering.","date":"2024","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/38516186","citation_count":2,"is_preprint":false},{"pmid":"33579784","id":"PMC_33579784","title":"Histone Methyltransferase NSD3 Is a Lung Squamous Cell Carcinoma Driver.","date":"2021","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33579784","citation_count":2,"is_preprint":false},{"pmid":"25036702","id":"PMC_25036702","title":"Wetting the whistle: neurotropic factor improves salivary function.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25036702","citation_count":2,"is_preprint":false},{"pmid":"40143436","id":"PMC_40143436","title":"NSD3: A Promising Target for Cancer Therapy.","date":"2025","source":"Cell biochemistry and function","url":"https://pubmed.ncbi.nlm.nih.gov/40143436","citation_count":1,"is_preprint":false},{"pmid":"40967468","id":"PMC_40967468","title":"The histone lysine methyltransferase NSD3 drives osteosarcomagenesis by inactivating ARID3A.","date":"2025","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/40967468","citation_count":1,"is_preprint":false},{"pmid":"40532307","id":"PMC_40532307","title":"H3K36 histone methyltransferase NSD3 functions as a multifaceted regulator of late erythropoiesis.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/40532307","citation_count":1,"is_preprint":false},{"pmid":"41360235","id":"PMC_41360235","title":"Histone methyltransferase NSD3 orchestrates early erythropoiesis by regulating erythroid progenitor cell differentiation and survival.","date":"2025","source":"Biochimica et biophysica acta. Molecular cell research","url":"https://pubmed.ncbi.nlm.nih.gov/41360235","citation_count":0,"is_preprint":false},{"pmid":"39741006","id":"PMC_39741006","title":"NSD3 protein methylation and stabilization transforms human ES cells into variant state.","date":"2024","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/39741006","citation_count":0,"is_preprint":false},{"pmid":"41970952","id":"PMC_41970952","title":"Histone methyltransferase G9a crosstalks with H3K36 histone methyltransferases NSD3 and SETD2 to mediate gene activation.","date":"2026","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/41970952","citation_count":0,"is_preprint":false},{"pmid":"40990092","id":"PMC_40990092","title":"NSD3::NUTM1 fusion evidenced on RNA sequencing in poorly differentiated thyroid cancer: a report of two cases.","date":"2025","source":"European thyroid journal","url":"https://pubmed.ncbi.nlm.nih.gov/40990092","citation_count":0,"is_preprint":false},{"pmid":"41727024","id":"PMC_41727024","title":"NSD3 stabilizes nuclear compartmentalization and promotes megabase-scale chromatin interactions.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41727024","citation_count":0,"is_preprint":false},{"pmid":"39285723","id":"PMC_39285723","title":"Thyroid Carcinoma With NSD3::NUTM1 Fusion and Secondary TERT Promoter Mutation: A Case Report and Literature Review.","date":"2024","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/39285723","citation_count":0,"is_preprint":false},{"pmid":"30236198","id":"PMC_30236198","title":"[NSD3 suppresses LPS-triggered TNF-α production via promoting the dimethylation of histone H3K36 in macrophages].","date":"2018","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30236198","citation_count":0,"is_preprint":false},{"pmid":"41820229","id":"PMC_41820229","title":"Fluorogenic Ligand Enables Identification of NSD3-Overexpressed Tumors by Targeting the PWWP1 Domain of NSD3.","date":"2026","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41820229","citation_count":0,"is_preprint":false},{"pmid":"42082455","id":"PMC_42082455","title":"The histone methyltransferase NSD3 oncogene triggers ribosomal DNA transcription, interfering with FOSL2 in cancer.","date":"2026","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/42082455","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.11.687848","title":"Loop Plasticity Drives Paralog-Specific Recognition in BET ET Domains","date":"2025-11-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.11.687848","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.29.685249","title":"Inhibitory-stabilization is sufficient for history-dependent computation in a randomly connected attractor network","date":"2025-10-30","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.29.685249","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.12.648498","title":"Nightingales imitate the duration of whistle syllables","date":"2025-04-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.12.648498","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.16.654575","title":"Mechanisms and control of a novel vocalization: The singing mouse song is a whistle that depends on air sac inflation","date":"2025-05-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.16.654575","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.21.647658","title":"First evidence for widespread sharing of stereotyped non-signature whistle types by wild dolphins","date":"2025-04-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.21.647658","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.11.664350","title":"RACLET: the Ramp Above Critical Level Endurance Test to evaluate critical velocity in running","date":"2025-07-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.11.664350","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.15.618471","title":"Whistle variability and social acoustic interactions in bottlenose dolphins","date":"2024-10-16","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.15.618471","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.07.642090","title":"Shared PRAME Epitopes are T-Cell Targets in NUT Carcinoma","date":"2025-03-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.07.642090","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.02.14.638254","title":"Zebra finches produce intralaryngeal laminar flow whistles during panting","date":"2025-02-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.02.14.638254","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.13.632779","title":"Courtship vocalizations in male ducks: spectral composition and resonance of the syringeal bulla","date":"2025-01-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.13.632779","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.10.607446","title":"H3K36 Methylation - a Guardian of Epigenome Integrity","date":"2024-08-10","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.10.607446","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43057,"output_tokens":7226,"usd":0.11878,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16344,"output_tokens":5643,"usd":0.111397,"stage2_stop_reason":"end_turn"},"total_usd":0.230177,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"NSD3 (WHSC1L1) encodes a SET domain-containing protein with two PWWP domains, five PHD zinc finger motifs, a SAC domain, and a SET domain, and maps to chromosome 8p12; it is amplified in breast cancer cell lines.\",\n      \"method\": \"Genomic cloning, domain analysis, FISH/chromosomal mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — initial characterization with domain identification and chromosomal mapping across two independent papers (PMID:11374904, PMID:11549311), but no functional reconstitution\",\n      \"pmids\": [\"11374904\", \"11549311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"NSD3/WHISTLE methylates histone H3-K4 and H3-K27 to repress transcription, induces apoptosis via caspase-3 activation dependent on its HMTase activity, and recruits HDAC1 through its N-terminal PWWP region. The SET domain cysteine 297 is critical for HMTase activity, and the PWWP domain is required for HMTase activity by interacting with associating factors.\",\n      \"method\": \"Deletion mapping, point mutagenesis, in vitro HMTase assay, caspase-3 activation assay, reporter assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis and in vitro activity assays in a single lab with multiple orthogonal methods\",\n      \"pmids\": [\"17239852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NSD3/WHISTLE interacts with heat shock protein HSP90α and the histone demethylase JMJD1C in a complex (identified by immunoaffinity TAP analysis). WHISTLE is recruited to the p450c17 promoter via SF-1 and represses transcription at prepubertal stages; JMJD1C then replaces WHISTLE to activate target gene expression during mouse testis development.\",\n      \"method\": \"Immunoaffinity TAP purification, ChIP, reporter assays, RT-PCR\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — TAP purification identifying complex plus ChIP demonstrating chromatin recruitment, single lab\",\n      \"pmids\": [\"20530532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NSD3 interacts with the extraterminal (ET) domain of BRD4 (and BRD2/BRD3); this interaction is required for pTEFb-independent transcriptional activation. NSD3 is recruited to BRD4 target genes in a BRD4-dependent manner and depletion of BRD4 or NSD3 reduces H3K36 methylation at target genes.\",\n      \"method\": \"Proteomic pulldown/Co-IP, ChIP, siRNA knockdown, transcriptional reporter assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP for recruitment, functional reporter assay, and histone modification readout in one study; independently corroborated by subsequent structural paper\",\n      \"pmids\": [\"21555454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The PHD5-C5HCH module of NSD3 forms a novel integrated PHD-PHD-like structural module that binds histone H3 N-terminal peptides, recognizing unmodified H3K4 and trimethylated H3K9 (H3K9me3) via PHD5. This binding specificity differs from NSD1 (which does not bind H3 peptides) and NSD2 (which prefers H3K9me0 over H3K9me3).\",\n      \"method\": \"Crystal structure determination (apo and H3 peptide-bound states), binding assays (ITC/NMR)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures in multiple states combined with binding assays in a single rigorous study\",\n      \"pmids\": [\"23269674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"WHSC1L1/NSD3 knockdown causes G2/M cell cycle arrest followed by multinucleation in bladder and lung cancer cell lines, and H3K36 dimethylation (H3K36me2) is reduced; downstream transcriptional targets include CCNG1 and NEK7.\",\n      \"method\": \"siRNA knockdown, cell cycle analysis (FACS), gene expression profiling (Affymetrix GeneChip)\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD with defined cellular phenotype and gene expression profiling, single lab\",\n      \"pmids\": [\"23011637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NSD3 is required for neural crest specification: it is expressed in premigratory and migratory neural crest cells, and is necessary for expression of neural plate border gene Msx1 and neural crest transcription factors Sox10, Snail2, Sox9, and FoxD3. H3K36me2 at the Sox10 locus specifically requires NSD3. A separate, direct requirement for NSD3-related methyltransferase activity exists during neural crest migration (shown by dominant-negative approach restricted to migratory stages).\",\n      \"method\": \"In situ hybridization, morpholino knockdown, dominant-negative expression (temporal restriction), ChIP for H3K36me2\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined transcriptional phenotypes and H3K36me2 ChIP, single lab\",\n      \"pmids\": [\"25318671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"NSD3-NUT fusion oncoprotein is both necessary and sufficient for blockade of differentiation and maintenance of proliferation in NUT midline carcinoma (NMC) cells. NSD3-NUT binds to BRD4, and BRD4 bromodomain inhibitors reverse its oncogenic effects. NSD3 itself is required for the differentiation block in BRD4-NUT-expressing NMC cells.\",\n      \"method\": \"Patient-derived cell line establishment, shRNA knockdown, rescue experiments, Co-IP (NSD3-NUT:BRD4 interaction), BET bromodomain inhibitor treatment with differentiation assay\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — necessity and sufficiency experiments, Co-IP, pharmacological validation, replicated across multiple NMC cell lines\",\n      \"pmids\": [\"24875858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"AML maintenance by BRD4 requires its interaction with the short isoform of NSD3 (NSD3-short), which lacks the methyltransferase domain. NSD3-short acts as an adaptor linking BRD4 (via BRD4 ET domain) to the CHD8 chromatin remodeler, using a PWWP chromatin reader module and an acidic transactivation domain. BRD4, NSD3, and CHD8 co-localize at super-enhancers across the AML genome and are co-released upon BET inhibition.\",\n      \"method\": \"CRISPR/Cas9 and shRNA knockdown (NSD3, CHD8), domain truncation analysis, Co-IP, ChIP-seq (BRD4/NSD3/CHD8 co-localization), RNA-seq, BET inhibitor treatment\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, ChIP-seq, genetic knockouts, transcriptomics), mechanistic isoform dissection, and genome-wide co-localization in single rigorous study\",\n      \"pmids\": [\"26626481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The ET domain of BRD4 recognizes an amphipathic sequence motif of NSD3 by establishing a two-strand antiparallel β-sheet anchored on a hydrophobic cleft of the ET domain three-helix bundle. This structural mechanism is required for BRD4-NSD3 interaction essential for AML maintenance.\",\n      \"method\": \"Crystal structure of BRD4 ET domain–NSD3 peptide complex, mutational analysis\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional validation of the interaction mechanism, single lab\",\n      \"pmids\": [\"27291650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"WHSC1L1/NSD3 enrichment and H3K36me2 at gene bodies of CDC6 and CDK2 directly regulates their transcription; WHSC1L1 knockdown causes G0/G1 arrest rescuable by wild-type but not enzyme-inactive WHSC1L1, demonstrating a requirement for catalytic activity in cell cycle progression.\",\n      \"method\": \"ChIP (WHSC1L1, H3K36me2), siRNA knockdown, rescue with wild-type vs. catalytic mutant, FACS cell cycle analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and catalytic mutant rescue, single lab\",\n      \"pmids\": [\"27285764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"WHSC1L1/NSD3 short isoform knockdown dramatically reduces ESR1 mRNA and ERα protein levels in SUM-44 breast cancer cells; loss of WHSC1L1 abrogates estrogen-independent ERα binding to chromatin (assessed by ChIP-Seq), which is restored by estradiol.\",\n      \"method\": \"siRNA/shRNA knockdown, ChIP-Seq, Western blot, RT-qPCR\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-Seq and genetic knockdown with defined molecular phenotype, single lab\",\n      \"pmids\": [\"27005559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NSD3/WHSC1L1 directly mono-methylates lysine 721 in the tyrosine kinase domain of EGFR; this methylation enhances ERK cascade activation without EGF and increases nuclear EGFR interaction with PCNA, promoting DNA synthesis and cell cycle progression in head and neck squamous cell carcinoma.\",\n      \"method\": \"In vitro methylation assay (mass spectrometry identification of K721me1), Co-IP (EGFR-PCNA), siRNA knockdown, cell cycle/DNA synthesis assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro methylation assay with MS validation of site, plus functional cell-based assays, single lab\",\n      \"pmids\": [\"28102297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NSD3 directly methylates IRF3 at K366 (monomethylation) via its SET domain; NSD3 binds the IRF3 C-terminal region through its PWWP1 domain (identified by mass spectrometry of IRF3-associated proteins). K366 monomethylation enhances IRF3 transcriptional activity by promoting IRF3 dissociation from protein phosphatase PP1cc, thereby maintaining IRF3 phosphorylation and type I interferon production. NSD3 deficiency impairs antiviral innate immune response in vivo.\",\n      \"method\": \"Mass spectrometry of IRF3-associated proteins, in vitro methylation assay (NSD3 SET domain), domain mapping (PWWP1 binding), Co-IP (NSD3-IRF3, IRF3-PP1cc), site-directed mutagenesis (K366), interferon production assay, in vivo NSD3 knockout\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation assay with site identification by MS, mutagenesis, Co-IP domain mapping, and in vivo KO phenotype in single study\",\n      \"pmids\": [\"29101251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NSD3-short (NSD3S) interacts with MYC (c-Myc), as detected by cell lysate-based TR-FRET assay, identifying a protein-protein interaction relevant to NSD3S oncogenic activity.\",\n      \"method\": \"TR-FRET assay (Flag-NSD3, GST-MYC in HEK293T lysates), orthogonal protein-protein interaction assay\",\n      \"journal\": \"Assay and drug development technologies\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, cell lysate-based indirect detection without reciprocal Co-IP validation\",\n      \"pmids\": [\"29634317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The PWWP1 domain of NSD3 is required for cancer cell viability; BI-9321, a fragment-based chemical probe, targets the methyl-lysine binding site of NSD3-PWWP1 with sub-micromolar in vitro affinity, engages the target at 1 µM in cells, and downregulates Myc mRNA expression, reducing proliferation in MOLM-13 AML cells.\",\n      \"method\": \"Fragment-based drug discovery (NMR, X-ray crystallography of probe-PWWP1 complex), cellular target engagement assay, qRT-PCR (Myc expression), cell proliferation assay\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural characterization of PWWP1-ligand complex combined with cellular target engagement and functional readout in a single rigorous study\",\n      \"pmids\": [\"31285596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NSD3 overexpression activates ERK1/2 signaling and enhances CAPG expression in colorectal cancer cells, promoting proliferation and migration; these effects are partially reversed by ERK1/2 inhibitor (PD98059) or CAPG siRNA.\",\n      \"method\": \"siRNA knockdown, overexpression, Western blot (ERK1/2 phosphorylation), cell proliferation and migration assays, pharmacological inhibition\",\n      \"journal\": \"OncoTargets and therapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, indirect pathway measurement without direct biochemical demonstration of ERK activation mechanism\",\n      \"pmids\": [\"31190890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NSD3 long isoform (full-length, with catalytic domain), but not the short isoform lacking the catalytic domain, cooperates with EZH2 and RNA polymerase II to drive H3K36me2/3-dependent transactivation of genes associated with NOTCH receptor cleavage, leading to nuclear accumulation of NICD and NICD-mediated transcriptional repression of E-cadherin. This promotes breast cancer cell stemness, EMT, and metastasis.\",\n      \"method\": \"Isoform-specific knockdown/overexpression, ChIP (H3K36me2/3, RNA Pol II), Co-IP (NSD3-EZH2), NOTCH pathway reporter, NICD nuclear localization assay, E-cadherin promoter ChIP, in vivo mouse tumor model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (ChIP, Co-IP, isoform dissection, in vivo), single lab\",\n      \"pmids\": [\"32967925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NSD3 is a catalytically active H3K36me2 methyltransferase and a key driver of lung squamous cell carcinoma (LUSC). An LUSC-associated variant NSD3(T1232A) shows increased catalytic activity for H3K36me2 in vitro and in vivo due to structural changes that relieve auto-inhibition. Expression of NSD3(T1232A) accelerates tumorigenesis in mouse models of LUSC. NSD3-dependent oncogenic activity requires its catalytic activity and promotes oncogenic gene expression via chromatin landscape reprogramming. NSD3-amplified/mutant LUSCs are hypersensitive to bromodomain inhibition.\",\n      \"method\": \"In vitro methylation assays, structural dynamic analysis (MD simulations), mouse LUSC models (KO and knock-in), patient-derived xenograft, CRISPR/Cas9, ChIP (H3K36me2), gene expression profiling, BET inhibitor treatment\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation reconstitution, structural analysis, multiple in vivo mouse models, and patient-derived xenograft, multiple orthogonal methods\",\n      \"pmids\": [\"33536620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NSD3 PROTAC degrader MS9715 (linking BI-9321/PWWP1 antagonist to VHL E3 ligase ligand) achieves selective NSD3 degradation and suppresses both NSD3 and cMyc oncogenic transcriptional programs in hematological cancer cells, with superior efficacy over PWWP1 blockade alone.\",\n      \"method\": \"PROTAC degradation assay, Western blot, transcriptomic profiling (RNA-seq), CRISPR-Cas9 NSD3 KO comparison, cell growth assay\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological degradation with genetic KO comparison and transcriptomic profiling, single lab\",\n      \"pmids\": [\"34469831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NSD3 is essential for mitotic sister chromatid cohesion: the long isoform interacts with the cohesin loader complex kollerin (NIPBL-MAU2) and promotes chromatin recruitment of MAU2 and cohesin at mitotic exit. NSD3 associates with chromatin in early anaphase prior to MAU2 and RAD21 recruitment, and its methyltransferase activity is required for efficient sister chromatid cohesion.\",\n      \"method\": \"Co-IP (NSD3-NIPBL/MAU2), ChIP (NSD3, MAU2, RAD21), siRNA knockdown with cohesion assay (sister chromatid separation), isoform-specific rescue, methyltransferase-dead mutant rescue\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP, functional cohesion assay, and methyltransferase-dead mutant in single study, single lab\",\n      \"pmids\": [\"37288770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NSD3 deposits H3K36me2 specifically at active promoters and enhancers (in contrast to NSD1/NSD2 which deposit H3K36me2 at broad intergenic regions). In the hierarchy of H3K36me1/2 deposition, NSD1 > NSD2 > NSD3 > ASH1L.\",\n      \"method\": \"Systematic genetic perturbations (single and combinatorial KO) in mouse mesenchymal stem cells, ChIP-seq (H3K36me1/2/3), comparative genomic analysis\",\n      \"journal\": \"Genome biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic multi-KO approach with genome-wide ChIP-seq across five methyltransferases, published in peer-reviewed journal\",\n      \"pmids\": [\"39390582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NSD3 forms a trimer with PPP1CB and p-STAT3 at the protein level (Co-IP), facilitating PPP1CB-mediated dephosphorylation of STAT3, which suppresses HK2 transcription and glycolysis in lung adenocarcinoma cells. This is a non-epigenetic function of NSD3.\",\n      \"method\": \"Co-IP (NSD3-PPP1CB-p-STAT3 trimer), Western blot (p-STAT3 levels), ChIP (HK2 promoter), glycolysis assay (glucose uptake, lactate production), siRNA knockdown\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifying trimer, functional phosphatase assay readout, and glycolysis measurements; single lab\",\n      \"pmids\": [\"39119928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"EHMT2 interacts with and methylates NSD3 at lysine 477, stabilizing NSD3 protein levels in variant human embryonic stem cells; NSD3 protein levels are regulated by protein degradation in normal hESCs, and methylation-mediated stabilization drives oncogenic transformation.\",\n      \"method\": \"Co-IP (EHMT2-NSD3), mass spectrometry identification of K477 methylation, NSD3 knockdown rescue experiments, protein stability assay (cycloheximide chase), cell transformation assays\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with MS identification of methylation site plus functional protein stability assays; single lab\",\n      \"pmids\": [\"39741006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The short isoform of NSD3 (NSD3S, lacking methyltransferase domain) is upregulated by impaired CUL3-ZBTB2 E3 ubiquitin ligase-mediated degradation; ATR kinase drives localization of NSD3S to stalled replication forks where it antagonizes PTIP-dependent MRE11 nuclease recruitment, protecting nascent DNA from degradation and stabilizing stalled forks, thereby conferring PARP inhibitor resistance in prostate cancer.\",\n      \"method\": \"Co-IP (NSD3S-PTIP, NSD3S-MRE11), proximity ligation assay (NSD3S at replication forks), iPOND (isolation of proteins on nascent DNA), siRNA/shRNA knockdown, PROTAC degradation, cell-line and PDX xenograft models, PARP inhibitor sensitivity assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, iPOND/fork protection assay, PROTAC degradation), in vivo PDX validation, and mechanistic isoform dissection in a single rigorous study\",\n      \"pmids\": [\"40578344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NSD3 long isoform (NSD3L) localizes to the nucleolus, binds nucleolar proteins, and triggers ribosomal DNA (rDNA) transcription by promoting Polymerase I and UBTF binding to the rDNA locus, while displacing the transcriptional repressor FOSL2 from the rDNA upstream region. NSD3L also prevents deposition of repressive H4K20me3 by competing with SUV4-20H.\",\n      \"method\": \"Unbiased mass spectrometry (nucleolar protein binding), ChIP (Pol I, UBTF, FOSL2, H4K20me3 on rDNA), NSD3L knockout/ablation, nucleolar localization by imaging, rRNA expression assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS identification of nucleolar partners, ChIP on rDNA locus for multiple factors, functional rRNA output assay; single lab\",\n      \"pmids\": [\"42082455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"NSD3 (via its long isoform) mediates chromosome folding in NUT carcinoma cells: it stabilizes the BRD4-NUT fusion oncoprotein on chromatin, promotes H3K36me2, and supports BRD4-NUT nuclear condensates; NSD3 loss attenuates distant chromatin interactions between BRD4-NUT megadomains. In fusion-negative cells, NSD3-short (catalytically inactive) promotes long-range chromatin contacts (>megabases) in a PWWP domain-dependent manner.\",\n      \"method\": \"Hi-C/chromatin conformation capture, ChIP-seq (H3K36me2, BRD4-NUT), CRISPR NSD3 knockout, domain-mutant NSD3 (PWWP mutant), live-cell imaging of condensates, fractionation\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Hi-C and ChIP-seq with genetic KO and domain mutant, but preprint only\",\n      \"pmids\": [\"41727024\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"NSD3 is a histone H3K36 mono/dimethyltransferase that deposits H3K36me2 preferentially at active promoters and enhancers; it exists in a catalytically active long isoform and a short isoform (NSD3S) lacking the SET domain that functions as a chromatin adaptor linking BRD4 (via its ET domain, through a defined amphipathic motif interaction) to the CHD8 remodeler; it also directly methylates non-histone substrates including IRF3 (K366) to promote interferon production and EGFR (K721) to enhance oncogenic signaling, is itself stabilized by EHMT2-mediated K477 methylation, promotes cohesin loading at mitotic exit through interaction with the kollerin complex (NIPBL-MAU2), drives rDNA transcription by displacing FOSL2 and competing with SUV4-20H at rDNA, and in its short isoform localizes to stalled replication forks (ATR-dependent) to protect nascent DNA by antagonizing MRE11 recruitment, thereby conferring PARP inhibitor resistance.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NSD3 (WHSC1L1) is a multidomain SET-domain histone methyltransferase that deposits H3K36 mono/dimethylation specifically at active promoters and enhancers, distinguishing it from the broad intergenic H3K36me2 patterns laid down by NSD1 and NSD2 [#0, #21]. Its catalytic activity drives transcription of cell-cycle genes such as CDC6 and CDK2, and enzyme-dead mutants fail to rescue the proliferation defects of NSD3-depleted cells, establishing a direct catalytic requirement for cell-cycle progression [#5, #10]. NSD3 also acts as a developmental regulator, supplying H3K36me2 required for neural crest specification gene expression [#6]. Histone-tail engagement is structurally encoded: an integrated PHD5-C5HCH module reads unmodified H3K4 and H3K9me3, while a PWWP1 methyl-lysine reader module is essential for cancer-cell viability and serves as a druggable pocket targeted by the BI-9321 chemical probe and the MS9715 PROTAC degrader, both of which suppress NSD3- and cMyc-driven transcriptional programs [#4, #15, #19]. NSD3 is expressed as a catalytically active long isoform and a short isoform (NSD3S) lacking the SET domain that functions as a chromatin adaptor: NSD3S bridges BRD4 \\u2014 through a defined amphipathic motif that forms an antiparallel \\u03b2-sheet on the BRD4 ET-domain three-helix bundle \\u2014 to the CHD8 remodeler, and this adaptor function sustains acute myeloid leukemia and the differentiation block of NUT midline carcinoma [#3, #8, #9, #7]. Beyond chromatin, NSD3 methylates non-histone substrates, monomethylating EGFR at K721 to potentiate oncogenic ERK signaling and IRF3 at K366 to enhance type I interferon production by displacing PP1cc and maintaining IRF3 phosphorylation [#12, #13]. The long isoform additionally promotes mitotic sister-chromatid cohesion by recruiting the kollerin (NIPBL-MAU2) cohesin loader at mitotic exit, while NSD3S protects stalled replication forks in an ATR-dependent manner by antagonizing MRE11 recruitment, conferring PARP-inhibitor resistance [#20, #24]. NSD3 is recurrently amplified and mutated in epithelial cancers, and a catalytically hyperactive variant (T1232A) accelerates lung squamous cell carcinoma, defining NSD3 as an oncogenic methyltransferase whose tumors are hypersensitive to bromodomain inhibition [#0, #18].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing the domain architecture and genomic location framed NSD3 as a candidate chromatin-modifying enzyme amplified in cancer.\",\n      \"evidence\": \"Genomic cloning, domain analysis, and FISH mapping to 8p12 in breast cancer cell lines\",\n      \"pmids\": [\"11374904\", \"11549311\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No catalytic activity reconstituted\", \"Substrate specificity unknown at this stage\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"First functional dissection assigned methyltransferase activity to the SET domain and a regulatory role to the PWWP region, though the histone substrate assignment differs from later consensus.\",\n      \"evidence\": \"Deletion mapping, point mutagenesis (C297), in vitro HMTase and caspase-3 assays\",\n      \"pmids\": [\"17239852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reported H3K4/H3K27 substrate not concordant with later H3K36 consensus\", \"Single-lab in vitro context\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying the BRD4 ET-domain interaction explained how NSD3 is targeted to active genes and coupled to pTEFb-independent transcription.\",\n      \"evidence\": \"Co-IP, ChIP recruitment, siRNA knockdown, reporter assay, H3K36 methylation readout\",\n      \"pmids\": [\"21555454\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which isoform mediates the interaction\", \"Structural basis not yet defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Crystallography of the PHD5-C5HCH module and cell-cycle knockdown studies defined how NSD3 reads histone tails and linked its loss to mitotic defects.\",\n      \"evidence\": \"Crystal structures with H3 peptides plus ITC/NMR binding; siRNA with FACS cell-cycle analysis and expression profiling\",\n      \"pmids\": [\"23269674\", \"23011637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of H3K9me3 recognition in vivo unresolved\", \"Connection between reader binding and catalysis not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Loss-of-function in neural crest and the discovery of the NSD3-NUT fusion oncoprotein established NSD3 in both normal development and oncogenic gene-regulatory programs through BRD4.\",\n      \"evidence\": \"Morpholino/dominant-negative with H3K36me2 ChIP in embryo; patient cell lines, shRNA, rescue, Co-IP, BET inhibitor in NUT carcinoma\",\n      \"pmids\": [\"25318671\", \"24875858\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct catalytic versus scaffold contribution to NUT carcinoma not separated at this point\", \"In vivo developmental substrate scope incomplete\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Isoform dissection revealed that the catalytically inactive short isoform, not the methyltransferase, is the adaptor coupling BRD4 to CHD8 at super-enhancers, redefining NSD3's role in AML.\",\n      \"evidence\": \"CRISPR/shRNA, domain truncation, Co-IP, BRD4/NSD3/CHD8 ChIP-seq co-localization, RNA-seq, BET inhibition\",\n      \"pmids\": [\"26626481\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of CHD8 engagement structurally undefined here\", \"Whether catalytic isoform contributes independently unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Structural and functional work converged to define the BRD4-ET\\u2013NSD3 amphipathic interface and to nail down a strict catalytic requirement for cell-cycle gene transcription and ER\\u03b1 chromatin binding.\",\n      \"evidence\": \"Crystal structure of ET\\u2013NSD3 peptide complex; catalytic-mutant rescue ChIP at CDC6/CDK2; ChIP-seq of ER\\u03b1 in breast cancer\",\n      \"pmids\": [\"27291650\", \"27285764\", \"27005559\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How catalytic and scaffold functions are partitioned between isoforms in the same cell remains unclear\", \"ER\\u03b1 regulatory mechanism downstream of NSD3 undefined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of EGFR-K721 and IRF3-K366 as direct substrates extended NSD3 beyond histones into oncogenic signaling and antiviral immunity.\",\n      \"evidence\": \"In vitro methylation with MS site mapping, domain mapping, Co-IP, mutagenesis, interferon assays, in vivo NSD3 knockout\",\n      \"pmids\": [\"28102297\", \"29101251\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full non-histone substrate repertoire unknown\", \"In vivo stoichiometry and dynamics of these methylations not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"An NSD3S\\u2013MYC interaction was reported, hinting at a direct link to the Myc oncogenic program.\",\n      \"evidence\": \"Cell lysate TR-FRET assay between Flag-NSD3 and GST-MYC\",\n      \"pmids\": [\"29634317\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Indirect lysate-based detection without reciprocal Co-IP validation\", \"No structural or cellular confirmation of the interaction\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Chemical-probe and PROTAC development validated the PWWP1 methyl-lysine pocket as a tractable target whose engagement downregulates Myc and impairs leukemia growth.\",\n      \"evidence\": \"Fragment-based discovery with NMR/X-ray of probe-PWWP1 complex, cellular target engagement, qRT-PCR, proliferation; colorectal overexpression studies\",\n      \"pmids\": [\"31285596\", \"31190890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic link between PWWP1 occupancy and Myc transcription incompletely defined\", \"Colorectal ERK/CAPG axis (Low confidence) lacks direct biochemical demonstration\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Isoform-specific work showed the long catalytic isoform cooperates with EZH2 and Pol II to drive NOTCH-dependent EMT and metastasis, distinguishing catalytic from adaptor functions.\",\n      \"evidence\": \"Isoform knockdown/overexpression, H3K36me2/3 and Pol II ChIP, NSD3-EZH2 Co-IP, NOTCH reporter, in vivo tumor model\",\n      \"pmids\": [\"32967925\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct NSD3-EZH2 structural interface not defined\", \"Single-lab context\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Comprehensive in vivo and structural work established NSD3 as a bona fide H3K36me2 oncogenic driver in LUSC and showed a hyperactive variant relieves auto-inhibition to accelerate tumorigenesis.\",\n      \"evidence\": \"In vitro methylation, MD simulations, mouse KO/knock-in LUSC models, PDX, CRISPR, ChIP, BET inhibition; PROTAC MS9715 degradation with KO comparison\",\n      \"pmids\": [\"33536620\", \"34469831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous regulators of the auto-inhibitory conformation in normal cells unknown\", \"Relationship between catalytic LUSC driving and BET-inhibitor sensitivity mechanistically incomplete\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"NSD3 was assigned a mitotic role, with the long isoform recruiting the kollerin cohesin loader and requiring catalytic activity for sister-chromatid cohesion.\",\n      \"evidence\": \"Co-IP with NIPBL/MAU2, ChIP of NSD3/MAU2/RAD21, cohesion assays, isoform- and methyltransferase-dead rescue\",\n      \"pmids\": [\"37288770\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Methyl substrate underlying cohesion promotion not identified\", \"Single-lab finding awaiting independent confirmation\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Multiple studies refined NSD3's genomic targeting specificity, identified additional non-epigenetic and regulatory functions, and defined how NSD3 itself is post-translationally stabilized.\",\n      \"evidence\": \"Systematic multi-KO ChIP-seq in mesenchymal stem cells; NSD3-PPP1CB-pSTAT3 trimer Co-IP and glycolysis assays; EHMT2-NSD3 Co-IP with K477 methylation MS and stability assays\",\n      \"pmids\": [\"39390582\", \"39119928\", \"39741006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism directing NSD3 specifically to active promoters/enhancers undefined\", \"Generality of the STAT3 trimer function beyond lung adenocarcinoma unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"New work defined isoform-segregated functions in genome stability and rDNA transcription, with NSD3S protecting stalled forks (PARPi resistance) and NSD3L driving Pol I transcription in the nucleolus.\",\n      \"evidence\": \"Co-IP, PLA, iPOND fork protection, PROTAC, PDX and PARPi assays; nucleolar MS, rDNA ChIP of Pol I/UBTF/FOSL2/H4K20me3, NSD3L ablation\",\n      \"pmids\": [\"40578344\", \"42082455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether fork protection requires catalytic activity unresolved\", \"Direct methyl substrate at the rDNA locus not identified\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Chromosome-folding analyses linked NSD3 isoforms to 3D genome organization, stabilizing BRD4-NUT condensates and mediating long-range chromatin contacts.\",\n      \"evidence\": \"Hi-C, ChIP-seq, CRISPR KO, PWWP domain mutants, condensate imaging (preprint)\",\n      \"pmids\": [\"41727024\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Mechanism by which catalytically inactive NSD3S drives megabase-scale contacts undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How NSD3 isoform choice, catalytic versus scaffold activities, genomic targeting, and its expanding non-histone substrate set are integrated into a single regulatory logic across normal and malignant cells remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking targeting specificity to substrate selection\", \"Endogenous control of long-versus-short isoform ratio incompletely defined\", \"Complete non-histone methylome unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [12, 13]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [5, 10, 18, 21]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [8, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 8, 20]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [8, 21, 24]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [8, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 10, 17]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [5, 10, 20]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"complexes\": [\"kollerin (NIPBL-MAU2)\"],\n    \"partners\": [\"BRD4\", \"CHD8\", \"EZH2\", \"NIPBL\", \"MAU2\", \"EHMT2\", \"PPP1CB\", \"PTIP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}